Results 191 to 200 of about 59,855 (258)
Some of the next articles are maybe not open access.
Clinical risk factors for the development of tardive dyskinesia.
Journal of Neurological Sciences, 2018BACKGROUND Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4 patients on current or previous antipsychotic treatment, including both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs).
Marco Solmi +3 more
semanticscholar +1 more source
S.S. Korsakov Journal of Neurology and Psychiatry, 2023
Tardive dyskinesia (TD) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. Prevention of TD is paramount, and clinicians should follow best practice recommendations for prescribing antipsychotics, as well as reduction the using of dopamine receptor blocking drugs for non ...
openaire +2 more sources
Tardive dyskinesia (TD) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. Prevention of TD is paramount, and clinicians should follow best practice recommendations for prescribing antipsychotics, as well as reduction the using of dopamine receptor blocking drugs for non ...
openaire +2 more sources
Antipsychotic-induced tardive dyskinesia: update on epidemiology and management
Current Opinion in Psychiatry, 2019Purpose of review To provide an update on the frequency of antipsychotic-induced tardive dyskinesia and its management in patients with schizophrenia spectrum disorders in studies published since the last systematic review in 2008. Recent findings Recent
C. Widschwendter, A. Hofer
semanticscholar +1 more source
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management
Psychiatry and Clinical Neurosciences, 2015Chanoch Miodownik, Vladimir Lerner
exaly +2 more sources
American Journal of Health-System Pharmacy, 1976
The etiology, pharmacology, treatment and possible prevention of tardive dyskinesia (TD) are discussed. This neurological disorder, characterized by involuntary movements of the lips, jaws and tongue, can occur as a result of short-term antipsychotic drug therapy, but usually occurs after long-term treatment.
K E, Clyne, R P, Juhl
openaire +3 more sources
The etiology, pharmacology, treatment and possible prevention of tardive dyskinesia (TD) are discussed. This neurological disorder, characterized by involuntary movements of the lips, jaws and tongue, can occur as a result of short-term antipsychotic drug therapy, but usually occurs after long-term treatment.
K E, Clyne, R P, Juhl
openaire +3 more sources
Historical perspectives on tardive dyskinesia.
Journal of Neurological Sciences, 2018Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with dopamine receptor blocking agents including antipsychotic medications.
S. Caroff +2 more
semanticscholar +1 more source
Genetics of tardive dyskinesia: Promising leads and ways forward.
Journal of Neurological Sciences, 2018Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder secondary to chronic use of dopamine receptor blocking medications. Genetic factors have been implicated in the etiology of TD.
C. Zai +5 more
semanticscholar +1 more source
Current Treatment Options in Neurology, 2011
Tardive dyskinesia (TD) is iatrogenic (drug-induced); hence the best strategy is prevention. Try to limit exposure to any dopamine receptor blocking agents (DRBAs) if possible. These agents may be unavoidable in some psychiatric conditions such as schizophrenia, but alternative therapies can be used in many situations, such as in the treatment of ...
Pratibha G, Aia +3 more
openaire +2 more sources
Tardive dyskinesia (TD) is iatrogenic (drug-induced); hence the best strategy is prevention. Try to limit exposure to any dopamine receptor blocking agents (DRBAs) if possible. These agents may be unavoidable in some psychiatric conditions such as schizophrenia, but alternative therapies can be used in many situations, such as in the treatment of ...
Pratibha G, Aia +3 more
openaire +2 more sources
Levetiracetam in Tardive Dyskinesia
Clinical Neuropharmacology, 2006The aim of this study was to evaluate the effect of levetiracetam on tardive dyskinesia (TD), which is known to be a major limitation of chronic antipsychotic drug therapy, particularly with conventional antipsychotics.Sixteen patients suffering from chronic psychosis with TD were enrolled consecutively.
MECO G +7 more
openaire +4 more sources
Tardive dyskinesia: Out of the shadows.
Journal of Neurological Sciences, 2018The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care.
R. Hauser, D. Truong
semanticscholar +1 more source